Literature DB >> 2877015

Therapeutic consequences of drug interactions with theophylline pharmacokinetics.

J H Jonkman.   

Abstract

Elimination of theophylline from the body occurs mainly (approximately 90%) by biotransformation, followed by excretion of the metabolites. Consequently, drugs affecting microsomal enzyme systems in the liver may alter the elimination of theophylline. Since theophylline has a rather narrow therapeutic window, dose adjustment might be necessary. Of the sympathomimetics, isoproterenol reduces theophylline clearance by 25%, but metaproterenol and terbutaline do not. Of the antibiotics, erythromycin and troleandomycin decrease theophylline clearance by 25% and 50%, respectively. No effect was observed with tetracycline, doxycycline, amoxicillin, cefaclor, and co-trimoxazole. On the other hand, rifampin (antituberculotic agent) increases theophylline clearance by 30%. Corticosteroids (hydrocortisone, methylprednisolone, and prednisone) do not affect theophylline kinetics. Influenza vaccination also has no influence. The antiulcerative agent (H2 antagonist) cimetidine decreases theophylline clearance by 30%, but the agent ranitidine does not have any effect. Oral contraceptives may decrease theophylline elimination by 30%. Barbiturates and phenytoin may enhance theophylline clearance substantially (up to 75%). If an interaction is expected, careful monitoring of theophylline plasma concentrations is required to optimize the dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877015     DOI: 10.1016/0091-6749(86)90054-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

2.  Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.

Authors:  J H Jonkman; K G Nicholson; P R Farrow; M Eckert; G Grasmeijer; B Oosterhuis; O E De Noord; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

3.  The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma.

Authors:  Seigo Korematsu; Kyoko Yamamoto; Tomokazu Nagakura; Hiroaki Miyahara; Naho Okazaki; Kensuke Akiyoshi; Tomoki Maeda; So-ichi Suenobu; Tatsuro Izumi
Journal:  Pediatr Allergy Immunol       Date:  2010-05       Impact factor: 6.377

4.  Proceedings of the British Pharmacological Society. Clinical Pharmacology Section. 14-16 April 1993. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

Review 5.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 6.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

7.  Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.

Authors:  R Dal Negro; C Pomari; P Turco
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

8.  Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy.

Authors:  A D Sperber
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

9.  Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.

Authors:  J H Jonkman; L Borgström; W J van der Boon; O E de Noord
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.